An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
NCT05025332
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Pitt Hopkins Syndrome
Interventions
DRUG:
NNZ-2591
Sponsor
Neuren Pharmaceuticals Limited